What is it about?
4 successful cases of rapidly progressive interstitial lung disease related to anti-MDA5 antibody positive amyopathic dermatomyositis treated with rituximab are discussed.
Featured Image
Why is it important?
The disease carries a very high mortality and is refractory to many traditional treatments.
Perspectives
This is the biggest cases series of successful treatment of the disease with rituximab so far.
Dr Ho So
Kwong Wah Hospital
Read the Original
This page is a summary of: Rituximab for refractory rapidly progressive interstitial lung disease related to anti-MDA5 antibody-positive amyopathic dermatomyositis, Clinical Rheumatology, April 2018, Springer Science + Business Media,
DOI: 10.1007/s10067-018-4122-2.
You can read the full text:
Contributors
The following have contributed to this page
